TC
CRSP icon

Truvestments Capital’s CRISPR Therapeutics CRSP Stock Holding History

Truvestments Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14
Closed -$876 – 754
2023
Q4 		$876 Hold
14
– – ﹤0.01% 716
2023
Q3 		$635 Hold
14
– – ﹤0.01% 642
2023
Q2 		$786 Hold
14
– – ﹤0.01% 641
2023
Q1 		$633 Buy
+14
New +$680 ﹤0.01% 629
2022
Q1 		– Sell
-14
Closed -$1K – 262
2021
Q4 		$1K Hold
14
– – ﹤0.01% 573
2021
Q3 		$2K Hold
14
– – ﹤0.01% 533
2021
Q2 		$2K Buy
+14
New +$1.7K ﹤0.01% 544

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Truvestments Capital's CRSP Position: Q1 2024 in Review

Truvestments Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 14 shares — an estimated $876 sold.

Truvestments Capital first reported a position in CRSP in Q2 2021 and held it in 7 quarters. The position peaked at $2K in Q3 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Truvestments Capital reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Truvestments Capital sold 14 CRISPR Therapeutics shares in Q1 2024, an estimated $876.
  • Truvestments Capital first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 7 quarters.
  • Truvestments Capital's CRISPR Therapeutics position peaked at $2K in Q3 2021.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Truvestments Capital's 13F filing for Q1 2024, filed 14 May 2024.